Using Artificial Intelligence to Discover New Antibiotics

Antibiotic resistance is a growing problem in treating bacterial infections. Specific bacteria in a colony can develop resistance to a certain antibiotic being used to treat it, and the resistance can then spread quickly through the bacterial population.

Antibiotic Resistant Bacteria

Image Credit: Kateryna Kon/

Resistance often means second-line antibiotics must be used to treat a patient. Such antibiotics are often less effective and can cause significant side effects. This can lead to longer treatments, making it more difficult for the patient to recover.

Where bacteria develop resistance to two or more antibiotics, it can make it very difficult to treat infections.

For example, in tuberculosis, resistance to first-line drugs (particularly rifampicin and isoniazid) has given rise to multiple drug-resistant tuberculosis which can increase treatment time from 9 to 18 months, while second-line drugs can cause harmful side effects such as nausea, diarrhea, and cardiac problems.

Overuse of antibiotics in animal agriculture, and misuse in general practice, has led to rising rates of antibiotic resistance. Therefore, new antibiotics are desperately needed. Traditional methods of development include experimental chemical synthesis and isolation of natural antibiotics.

However, over the past few decades, these methods have resulted in very few new antibiotics. There is often a high degree of error and it can be a very costly approach for pharmaceutical companies.

Artificial intelligence in antibiotic discovery

The purpose of using artificial intelligence is to enable predictions of new antibiotics that are structurally distinct from current antibiotics and that are also effective across a broad spectrum of bacteria. An antibiotic candidate would then be synthesized from a model and tested for antibiotic activity.


Image Credit: Fahroni/

Artificial neural networks have previously been used in this process. They are computing systems loosely based on biological neural networks that allow the system to ‘learn’. This permits a chemically accurate molecular structure to be predicted, which was not possible beforehand.

An artificial neural network can be trained to predict growth inhibition of a specific bacterial species based on a relatively small collection of molecules (2-3,000). This understanding can then be applied to much larger chemical libraries (>100 million molecules) to identify potential antibiotic candidates.

This reduces a lot of the trial and error involved in antibiotics development. A computing system such as this could predict antibiotic chemical structures with a high degree of accuracy, reducing resources spent on developing compounds with little antibiotic activity.

Discovery of halicin

A group of researchers at the Massachusetts Institute of Technology (MIT) have used this approach to identify the compound halicin, a c-Jun N-terminal kinase inhibitor. Halicin has subsequently shown bactericidal effects against drug-resistant strains of tuberculosis and carbapenem-resistant Enterobacteriaceae (CRE).

The ability to act against drug-resistant bacteria is partly due to an unusual mechanism of activity. Halicin alters the pH gradient across the bacterial cell membrane and therefore disrupts a variety of activities (including the production of ATP) that are essential for bacteria survival.

Halicin was subsequently tested in vivo in a mouse model infected with a strain of Acinetobacter baumannii resistant to all current antibiotics. Within 24 hours of application, the infection was completely cleared.

Additionally, resistance was shown to not develop in treated bacteria. Over a 30-day treatment period, Escherichia coli didn’t develop any resistance to halicin. Conversely, a control group treated with ciprofloxacin developed resistance within 1-3 days.

Halicin is still in the very early stages of development, with its safety and efficacy in humans yet to be determined. However, these initial results are very promising, particularly in its demonstrated bactericidal ability against multiple drug-resistant strains of bacteria.

The discovery of such a potentially powerful antibiotic early on in the use of artificial intelligence indicates the possibility for many other broad-spectrum antibiotics to be identified, which could be useful against a broad spectrum of bacteria.

Application of the technology to different, larger databases has helped to identify other potential antibiotic candidates. The database ZINC5 (including around 1.5 billion chemical compounds) was screened, finding 23 potential antibiotics that are structurally distinct from existing ones.


While the discovery of new antibiotics using artificial intelligence is exciting, there are many improvements within the technology and its use that could lead to further discoveries.

Computing is an evolving discipline and its application in chemical research is relatively new. Different approaches to the use of artificial intelligence in antibiotic discovery may yield even more exciting results.

It is also worth stating that artificial intelligence is also useful in other aspects of preventing further increases in antibiotic resistance. Its role in understanding the epidemiology of resistance is key to preventing further exacerbation of the issue.

Developing new antibiotics will be crucial to preventing deaths from resistant bacteria, and artificial intelligence is an excellent tool for this. Nevertheless, this approach should be combined with preventative strategies against the spread of resistance, as even with this technology there are only a finite number of different antibiotic compounds.


  • (2020) Artificial intelligence yields new antibiotic | MIT News. Available at: (Accessed: 18 March 2020).
  • Rodríguez-González, A., Zanin, M. and Menasalvas-Ruiz, E. (2019) ‘Public Health and Epidemiology Informatics: Can Artificial Intelligence Help Future Global Challenges? An Overview of Antimicrobial Resistance and Impact of Climate Change in Disease Epidemiology’, Yearbook of medical informatics. NLM (Medline), 28(1), pp. 224–231. doi: 10.1055/s-0039-1677910.
  • Stokes, J. M. et al. (2020) ‘A Deep Learning Approach to Antibiotic Discovery’, Cell. Cell Press, 180(4), pp. 688-702.e13. doi: 10.1016/j.cell.2020.01.021.

Further Reading

Last Updated: Apr 17, 2020

Gwillym Preece

Written by

Gwillym Preece

Gwillym has a strong passion for understanding new developments in science, particularly those within microbiology and infectious disease control. He has a B.Sc. in microbiology from the University of Sheffield where he gained knowledge in the molecular mechanisms of infectious disease, with a particular focus on tuberculosis and Staphylococcus aureus .


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Preece, Gwillym. (2020, April 17). Using Artificial Intelligence to Discover New Antibiotics. AZoLifeSciences. Retrieved on July 20, 2024 from

  • MLA

    Preece, Gwillym. "Using Artificial Intelligence to Discover New Antibiotics". AZoLifeSciences. 20 July 2024. <>.

  • Chicago

    Preece, Gwillym. "Using Artificial Intelligence to Discover New Antibiotics". AZoLifeSciences. (accessed July 20, 2024).

  • Harvard

    Preece, Gwillym. 2020. Using Artificial Intelligence to Discover New Antibiotics. AZoLifeSciences, viewed 20 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.